See more : Jupiter Wellness, Inc. (JUPW) Income Statement Analysis – Financial Results
Complete financial analysis of Mesa Laboratories, Inc. (MLAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mesa Laboratories, Inc., a leading company in the Hardware, Equipment & Parts industry within the Technology sector.
You may be interested
- GHP Specialty Care AB (publ) (GHP.ST) Income Statement Analysis – Financial Results
- Qiansui International Group Co. Ltd. (QIAN) Income Statement Analysis – Financial Results
- Aurizon Holdings Limited (AZJ.AX) Income Statement Analysis – Financial Results
- NRG Energy, Inc. (NRA.DE) Income Statement Analysis – Financial Results
- KNT Holdings Limited (1025.HK) Income Statement Analysis – Financial Results
Mesa Laboratories, Inc. (MLAB)
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216.19M | 219.08M | 184.34M | 133.94M | 117.69M | 103.14M | 96.18M | 93.67M | 84.66M | 71.33M | 52.72M | 46.44M | 39.62M | 32.83M | 21.93M | 21.54M | 19.56M | 17.24M | 11.58M | 10.04M | 9.13M | 9.08M | 9.04M | 9.10M | 8.66M | 8.10M | 7.90M | 7.80M | 8.10M | 6.60M | 6.20M | 4.40M | 3.80M | 3.50M | 2.80M | 1.10M | 1.00M |
| Cost of Revenue | 82.94M | 85.39M | 75.25M | 46.92M | 52.75M | 42.22M | 41.56M | 40.43M | 33.25M | 27.94M | 21.04M | 17.57M | 16.11M | 13.26M | 8.74M | 7.72M | 6.70M | 6.35M | 4.15M | 3.72M | 3.43M | 3.40M | 3.65M | 3.07M | 2.80M | 2.40M | 2.50M | 2.70M | 2.80M | 2.20M | 2.10M | 1.40M | 1.20M | 1.20M | 1.20M | 400.00K | 400.00K |
| Gross Profit | 133.25M | 133.69M | 109.09M | 87.01M | 64.93M | 60.92M | 54.62M | 53.24M | 51.41M | 43.39M | 31.69M | 28.86M | 23.51M | 19.57M | 13.19M | 13.82M | 12.86M | 10.90M | 7.44M | 6.32M | 5.70M | 5.68M | 5.39M | 6.03M | 5.85M | 5.70M | 5.40M | 5.10M | 5.30M | 4.40M | 4.10M | 3.00M | 2.60M | 2.30M | 1.60M | 700.00K | 600.00K |
| Gross Profit Ratio | 61.64% | 61.02% | 59.18% | 64.97% | 55.17% | 59.06% | 56.79% | 56.84% | 60.73% | 60.83% | 60.10% | 62.16% | 59.35% | 59.61% | 60.17% | 64.16% | 65.74% | 63.19% | 64.21% | 62.94% | 62.44% | 62.59% | 59.61% | 66.30% | 67.62% | 70.37% | 68.35% | 65.38% | 65.43% | 66.67% | 66.13% | 68.18% | 68.42% | 65.71% | 57.14% | 63.64% | 60.00% |
| Research & Development | 19.30M | 20.49M | 15.77M | 10.39M | 6.36M | 3.51M | 3.54M | 4.16M | 3.97M | 3.29M | 2.32M | 2.01M | 1.36M | 1.44M | 669.00K | 636.00K | 532.00K | 392.00K | 358.00K | 358.00K | 332.00K | 259.97K | 289.94K | 308.17K | 281.65K | 200.00K | 300.00K | 300.00K | 300.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 72.87M | 72.44M | 60.31M | 45.70M | 37.83M | 31.30M | 26.26M | 22.81M | 23.62M | 17.06M | 11.46M | 9.12M | 5.42M | 4.58M | 2.54M | 2.52M | 5.27M | 4.84M | 2.97M | 2.49M | 2.12M | 2.24M | 2.16M | 2.40M | 2.39M | 2.20M | 2.10M | 2.10M | 2.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 38.63M | 37.44M | 28.31M | 18.48M | 12.91M | 8.26M | 8.82M | 9.96M | 7.50M | 7.18M | 6.12M | 4.63M | 3.91M | 3.69M | 2.62M | 3.05M | 2.85B | 2.77B | 1.88B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 111.49M | 109.88M | 88.62M | 64.18M | 50.74M | 39.56M | 35.08M | 32.77M | 31.12M | 24.23M | 17.58M | 13.75M | 9.33M | 8.26M | 5.16M | 5.57M | 5.27M | 4.84M | 2.97M | 2.49M | 2.12M | 2.24M | 2.16M | 2.40M | 2.39M | 2.20M | 2.10M | 2.10M | 2.30M | 1.80M | 2.30M | 1.60M | 1.30M | 1.20M | 1.00M | 600.00K | 600.00K |
| Other Expenses | 274.53M | -3.71M | -1.13M | 91.00K | 50.00K | -1.16M | -1.88M | -2.02M | -768.00K | -517.00K | 1.32M | -126.00K | 350.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 332.59K | 200.00K | 200.00K | 200.00K | 300.00K | 300.00K | 200.00K | 100.00K | 100.00K | 200.00K | 100.00K | 0.00 | 0.00 |
| Operating Expenses | 406.55M | 130.37M | 104.39M | 74.66M | 57.14M | 43.06M | 38.62M | 36.93M | 35.09M | 27.53M | 19.90M | 15.76M | 10.68M | 9.70M | 5.83M | 6.21M | 5.80M | 5.24M | 3.33M | 2.85M | 2.45M | 2.50M | 2.45M | 2.71M | 3.01M | 2.60M | 2.60M | 2.60M | 2.90M | 2.50M | 2.50M | 1.70M | 1.40M | 1.40M | 1.10M | 600.00K | 600.00K |
| Cost & Expenses | 488.26M | 215.76M | 179.63M | 121.58M | 109.90M | 85.28M | 80.18M | 77.35M | 68.34M | 55.47M | 40.94M | 33.33M | 26.79M | 22.96M | 14.56M | 13.93M | 12.50M | 11.58M | 7.47M | 6.57M | 5.88M | 5.90M | 6.10M | 5.77M | 5.81M | 5.00M | 5.10M | 5.30M | 5.70M | 4.70M | 4.60M | 3.10M | 2.60M | 2.60M | 2.30M | 1.00M | 1.00M |
| Interest Income | 0.00 | 4.77M | 3.89M | 107.00K | 960.00K | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 195.00M | 130.00M | 193.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.70M | 3.71M | 3.89M | 8.02M | 5.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 31.57M | 33.13M | 25.07M | 17.47M | 12.87M | 9.47M | 9.47M | 8.74M | 7.17M | 5.66M | 3.84M | 3.43M | 2.22M | 1.84M | 786.00K | 788.00K | 742.00K | 669.00K | 93.00K | 90.00K | 97.00K | 115.35K | 115.09K | 521.69K | 332.59K | 200.00K | 200.00K | 200.00K | 300.00K | 300.00K | 200.00K | 100.00K | 100.00K | 200.00K | 100.00K | 0.00 | 0.00 |
| EBITDA | -238.38M | 36.45M | 29.77M | 12.36M | 8.09M | 18.09M | 9.77M | 25.05M | 23.50M | 21.52M | 15.63M | 16.54M | 14.55M | 11.71M | 8.15M | 8.40M | 7.80M | 6.33M | 4.20M | 3.57M | 3.35M | 3.30M | 3.06M | 3.85M | 3.18M | 3.30M | 3.20M | 2.70M | 2.70M | 2.20M | 1.80M | 1.40M | 1.30M | 1.10M | 600.00K | 100.00K | 0.00 |
| EBITDA Ratio | -110.26% | 1.52% | 2.55% | 9.23% | 6.87% | 34.28% | 31.01% | 17.42% | 19.28% | 22.24% | 22.35% | 28.22% | 39.22% | 36.01% | 33.76% | 38.99% | 39.90% | 36.70% | 36.29% | 35.50% | 36.66% | 36.36% | 33.80% | 43.13% | 36.72% | 37.04% | 35.44% | 33.33% | 32.10% | 33.33% | 29.03% | 29.55% | 31.58% | 31.43% | 21.43% | 9.09% | 0.00% |
| Operating Income | -272.08M | -30.50M | -20.37M | -5.30M | -4.90M | 9.78M | 2.18M | 16.31M | 16.32M | 15.86M | 11.79M | 13.10M | 12.48M | 9.86M | 7.37M | 7.61M | 7.06M | 5.66M | 4.11M | 3.48M | 3.25M | 3.19M | 2.94M | 2.81M | 2.85M | 3.10M | 2.80M | 2.50M | 2.40M | 1.90M | 1.60M | 1.30M | 1.20M | 900.00K | 500.00K | 100.00K | 0.00 |
| Operating Income Ratio | -125.85% | -13.92% | -11.05% | -3.96% | -4.16% | 9.48% | 2.27% | 17.42% | 19.28% | 22.24% | 22.35% | 28.22% | 31.49% | 30.05% | 33.60% | 35.33% | 36.10% | 32.82% | 35.48% | 34.61% | 35.60% | 35.09% | 32.53% | 30.84% | 32.87% | 38.27% | 35.44% | 32.05% | 29.63% | 28.79% | 25.81% | 29.55% | 31.58% | 25.71% | 17.86% | 9.09% | 0.00% |
| Total Other Income/Expenses | -3.57M | -3.71M | -1.13M | -10.06M | -4.06M | -1.16M | -1.88M | -2.02M | -768.00K | -517.00K | 1.32M | -126.00K | -146.00K | -113.00K | 36.00K | 86.00K | 195.00K | 130.00K | 193.00K | 98.00K | 50.00K | 55.16K | 78.51K | 70.96K | 243.83K | 100.00K | 400.00K | 100.00K | 0.00 | -100.00K | -100.00K | 0.00 | 100.00K | 100.00K | 0.00 | 100.00K | 0.00 |
| Income Before Tax | -275.65M | -389.00K | 3.57M | 2.30M | 3.43M | 8.62M | 301.00K | 14.30M | 15.56M | 15.35M | 13.10M | 12.98M | 12.33M | 9.75M | 7.40M | 7.69M | 7.26M | 5.79M | 4.30M | 3.57M | 3.30M | 3.24M | 3.02M | 2.88M | 3.09M | 3.20M | 3.20M | 2.60M | 2.40M | 1.80M | 1.50M | 1.30M | 1.30M | 1.00M | 0.00 | 200.00K | 0.00 |
| Income Before Tax Ratio | -127.50% | -0.18% | 1.94% | 1.72% | 2.92% | 8.36% | 0.31% | 15.26% | 18.37% | 21.52% | 24.85% | 27.95% | 31.13% | 29.71% | 33.76% | 35.73% | 37.10% | 33.57% | 37.15% | 35.58% | 36.15% | 35.69% | 33.40% | 31.62% | 35.69% | 39.51% | 40.51% | 33.33% | 29.63% | 27.27% | 24.19% | 29.55% | 34.21% | 28.57% | 0.00% | 18.18% | 0.00% |
| Income Tax Expense | -21.40M | -1.32M | 1.70M | -971.00K | 2.08M | 1.14M | 3.26M | 3.11M | 4.39M | 5.76M | 4.10M | 4.53M | 4.41M | 3.57M | 2.64M | 2.90M | 2.65M | 1.83M | 1.50M | 1.26M | 1.17M | 1.11M | 989.66K | 1.05M | 982.46K | 1.10M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 400.00K | 400.00K | 100.00K | 100.00K | 100.00K | 0.00 |
| Net Income | -254.25M | 930.00K | 1.87M | 3.27M | 1.35M | 7.48M | -2.96M | 11.18M | 11.17M | 9.58M | 9.00M | 8.45M | 7.92M | 6.18M | 4.77M | 4.79M | 4.61M | 3.96M | 2.81M | 2.31M | 2.13M | 2.13M | 2.03M | 1.83M | 2.11M | 2.10M | 2.10M | 1.70M | 1.60M | 1.20M | 1.00M | 900.00K | 900.00K | 900.00K | 400.00K | 100.00K | 0.00 |
| Net Income Ratio | -117.60% | 0.42% | 1.01% | 2.44% | 1.15% | 7.26% | -3.08% | 11.94% | 13.19% | 13.43% | 17.07% | 18.20% | 19.99% | 18.84% | 21.75% | 22.24% | 23.57% | 22.96% | 24.22% | 23.03% | 23.34% | 23.42% | 22.46% | 20.13% | 24.34% | 25.93% | 26.58% | 21.79% | 19.75% | 18.18% | 16.13% | 20.45% | 23.68% | 25.71% | 14.29% | 9.09% | 0.00% |
| EPS | -47.20 | 0.17 | 0.36 | 0.66 | 0.32 | 1.95 | -0.79 | 3.04 | 3.10 | 2.72 | 2.61 | 2.52 | 2.41 | 1.91 | 1.49 | 1.51 | 1.46 | 1.25 | 0.94 | 0.76 | 0.70 | 0.66 | 0.60 | 0.59 | 0.55 | 0.51 | 0.48 | 0.39 | 0.29 | 0.29 | 0.23 | 0.21 | 0.21 | 0.20 | 0.10 | 0.04 | 0.01 |
| EPS Diluted | -47.20 | 0.17 | 0.35 | 0.64 | 0.31 | 1.86 | -0.79 | 2.91 | 2.97 | 2.63 | 2.49 | 2.35 | 2.29 | 1.86 | 1.45 | 1.48 | 1.41 | 1.22 | 0.92 | 0.74 | 0.68 | 0.64 | 0.59 | 0.59 | 0.55 | 0.50 | 0.47 | 0.39 | 0.29 | 0.29 | 0.23 | 0.21 | 0.21 | 0.20 | 0.10 | 0.04 | 0.01 |
| Weighted Avg Shares Out | 5.39M | 5.32M | 5.21M | 4.98M | 4.20M | 3.84M | 3.75M | 3.68M | 3.61M | 3.52M | 3.45M | 3.36M | 3.29M | 3.23M | 3.19M | 3.18M | 3.17M | 3.16M | 2.99M | 3.06M | 3.05M | 3.23M | 3.41M | 3.69M | 3.82M | 4.14M | 4.30M | 4.47M | 4.33M | 4.14M | 4.35M | 4.29M | 4.29M | 4.50M | 4.00M | 2.50M | 3.48M |
| Weighted Avg Shares Out (Dil) | 5.39M | 5.36M | 5.34M | 5.12M | 4.37M | 4.03M | 3.77M | 3.84M | 3.76M | 3.65M | 3.61M | 3.59M | 3.46M | 3.33M | 3.29M | 3.24M | 3.28M | 3.23M | 3.05M | 3.14M | 3.14M | 3.30M | 3.45M | 3.72M | 3.84M | 4.17M | 4.40M | 4.47M | 4.33M | 4.14M | 4.35M | 4.29M | 4.29M | 4.50M | 4.00M | 2.50M | 3.48M |
Bull of the Day: Mesa Laboratories (MLAB)
Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division
Mesa Labs Declares Quarterly Dividend
Lakewood, Colo., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The...
Rendanheyi Now a Frequently Mentioned Term in Business Globally
QINGDAO, China--(BUSINESS WIRE)--From the Business Roundtable in the US redefining the purpose of a corporation to more manufacturing and Internet giants jumping on the bandwagon of organizational transformation, the management logic for the Internet of Things (IoT) era is changing...
未来に適応した経営モデルを当フォーラムに求めるべき理由
中国・青島--(BUSINESS WIRE)--（ビジネスワイヤ） -- 賢者は常に一歩先を行き、社会の発展を導こうとします。今回注目されたのは、東洋の海辺の都市、青島でした。 モノのインターネット（IoT）は、経済や社会のあり方をかつてないスピードと方法で変えています。従来の開発モデルは、次々と現れるユーザーのニーズに対応できません。古典的な経済理論に言う「人」の道具化が進んだことで貧富の差は拡大し、共通の繁栄を求める声がますます高まっています。しかし、技術や製品のイノベーションだけでは、その問題を解決することはできません。経営モデルのイノベーションこそが唯一の答えです。 多くの企業が経営の行き詰まりを打破しようと必死になる一方で、「人単合一」モデルを採用した企業は、将来への高い適応力を発揮しています。9月17日に青島で開催された第5回「人単合一モデル・リーディング・フォーラム」には、ノーベル経済学賞受賞者のエドマンド・フェルプス氏、マネジメント・ラボ（MLab）創設者のゲイリー・ハメル氏、量子経営理論の創始者であるダナー・ゾーハー氏、IMD教授のビル・フィッシャー氏、MLabマネジメント・ディレクターのミシェル・ザニーニ氏が出席しました。 この人々は、人単合一モデル（青島で考案された）が、なぜIoTの世界を解き放つ鍵となったのかを見出そうと意欲的でした。 エドマンド・フェルプス氏は、万人に共通の発展をもたらすためには、国や企業は「普通の人々」の可能性を引き出して広くイノベーションを起こさなければならないが、大規模な組織にはそのような必要とされるダイナミズムが欠けていることが多いと主張しました。個人の可能性を解放することのできる組織だけが、未来に居場所を維持できるのです。 人単合一モデルは、その条件を満たしました。それは、一人一人が自律した人間であることを重視します。それは、各人を命令の実行者から起業家パートナーへと変化させます。上司と部下を区別するのではなく、プラットフォームの所有者、零細企業の所有者、起業家という3種類の当事者だけが意識されます。この3種類の当事者は、主要な目標に向かって競い合い、その目標をめぐって集中（または分散）していきます。起業家精神を持っている人なら誰でも、ここで自己実現を図ることができます。 かつて張瑞敏最高経営責任者（CEO）は不良品の冷蔵庫を叩き壊し、同時に従業員の中にあった「自分にはできない」という考え方も退けました。そしてハイアールの製品は中国各地で販売されるようになりました。その後、張瑞敏は人単合一モデルを提唱し、階級を壊し、新しい企業経営モデルでIoT時代をリードする道を開きました。中国発の経営パラダイムである人単合一モデルは、2005年に初めて登場して以来、期待を上回り、経営革新に世界的な変革を起こしました。「人単合一モデル・フォーラム」を通じた16年間の反復と5年連続の改良を経て、ハイアールは成功を収めました。 どの国でも、どの国民でも、どの企業でも、人にはそれぞれが己の価値を発揮したいという普遍的な欲求があります。それこそが人単合一モデルの優れた価値提案であり、それは誰にでも適用でき、世界中で共有されます。 これまでに74カ国・地域で30万以上の組織が人単合一連合のメンバーとして登録しています。シリコンバレーをはじめ、世界各地に10カ所の人単合一センターが設立されています。いずれも現地の学者や起業家が開設したもので、この中国モデルから進むべき道を見つける期待がかかっています。 ハイアールグループの張瑞敏会長兼CEOは、中国企業が時代の機会を捉え、共にIoT時代のリーダーとなることを期待していると述べています。張瑞敏が提唱した人単合一モデルは、間違いなく私たちの最高のチャンスです。 本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。
Why Look to This Forum for a Management Model Adapted to the Future?
QINGDAO, China--(BUSINESS WIRE)--The wise always strive to remain one step ahead in navigating the path of advancing society. This time, they have set their eyes on Qingdao, the seaside city of the East. The Internet of Things (IoT) is changing...
Mesa Labs (MLAB) Moves 4.5% Higher: Will This Strength Last?
Mesa Labs (MLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mesa Labs Announces Agreement to Acquire Agena Bioscience, Inc.
LAKEWOOD, Colo., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “us”, “our”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries,...
Mesa Labs (MLAB) Lags Q1 Earnings Estimates
Mesa Labs (MLAB) delivered earnings and revenue surprises of -5.88% and 2.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., July 06, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa Labs” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock....
New Strong Sell Stocks for June 14th
CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021
Source: https://incomestatements.info
Category: Stock Reports